Latest Breaking News On - Companion diagnostic test - Page 9 : comparemela.com

Myriad Genetics (NASDAQ:MYGN) Downgraded by StockNews com

Myriad Genetics (NASDAQ:MYGN – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday. Several other analysts also recently issued reports on MYGN. JPMorgan Chase & Co. decreased their target price on Myriad Genetics from $18.00 to $17.00 and […]

United statesGoldman sachs groupProshare advisorsRoyal bankJpmorgan chase coPricet rowe associates incUs bancorpGenetics company profileGenetics incAmeritas investment partners incMyriad geneticsGet free reportInvestment partnersShare advisorsMyrisk hereditary cancer testGermline companion diagnostic test

Analysts Set Myriad Genetics, Inc (NASDAQ:MYGN) PT at $24 20

Shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) have been assigned a consensus rating of “Hold” from the five analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating on the […]

United statesWealth managementGenetics company profileMirae asset global investments coGoldman sachs groupGenetics incSg americas securitiesJpmorgan chase coMyriad geneticsGet free reportAsset global investmentsGet freeMyrisk hereditary cancer testGermline companion diagnostic testCompanion diagnostic testMyriad genetics daily

Myriad Genetics (NASDAQ:MYGN) Now Covered by Analysts at StockNews com

StockNews.com began coverage on shares of Myriad Genetics (NASDAQ:MYGN – Free Report) in a report issued on Thursday morning. The brokerage issued a hold rating on the stock. Several other equities research analysts have also issued reports on the company. JPMorgan Chase & Co. dropped their price objective on Myriad Genetics from $18.00 to $17.00 […]

United statesGoldman sachs groupPricet rowe associates incProshare advisorsUs bancorpGenetics incJpmorgan chase coRoyal bankAmeritas investment partners incMyriad geneticsFree reportGet free reportInvestment partnersShare advisorsMyrisk hereditary cancer testGermline companion diagnostic test

Myriad Genetics (NASDAQ:MYGN) Stock Price Down 4%

Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) was down 4% during mid-day trading on Friday . The company traded as low as $15.99 and last traded at $16.12. Approximately 265,475 shares changed hands during trading, a decline of 53% from the average daily volume of 562,167 shares. The stock had previously closed at $16.79. […]

United statesHong kongGenetics incGoldman sachs groupHong kong ltdJpmorgan chase coTower research capitalRoyal bankUs bancorpMyriad geneticsGet free reportResearch capitalKong ltdMyrisk hereditary cancer testGermline companion diagnostic testCompanion diagnostic test

Leerink Partnrs Comments on Myriad Genetics, Inc s Q1 2024 Earnings (NASDAQ:MYGN)

Leerink Partnrs Comments on Myriad Genetics, Inc s Q1 2024 Earnings (NASDAQ:MYGN)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongLeerink partnrsRoyal bankGoldman sachs groupUs bancorpHong kong ltdJpmorgan chase coGenetics incTower research capitalMyriad geneticsFree reportMyriad geneticGet free reportResearch capitalKong ltd